Do neurobiological differences exist between paranoid and non-paranoid schizophrenia? Findings from the bipolar schizophrenia network on intermediate phenotypes study.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
09 2020
Historique:
received: 02 05 2019
revised: 23 10 2019
accepted: 26 02 2020
pubmed: 9 6 2020
medline: 22 6 2021
entrez: 9 6 2020
Statut: ppublish

Résumé

Subtypes of schizophrenia, constructed using clinical phenomenology to resolve illness heterogeneity, have faced criticism due to overlapping symptomatology and longitudinal instability; they were therefore dropped from the Diagnostic Statistical Manual-5. Cognitive and imaging findings comparing paranoid (P-SZ) and non-paranoid (disorganized, residual and undifferentiated; NP-SZ) schizophrenia have been limited due to small sample sizes. We assessed P-SZ and NP-SZ using symptomatology, cognition and brain structure and predicted that there would be few neurobiological differences. P-SZ (n = 237), NP-SZ (n = 127) and controls (n = 430) were included from a multi-site study. In a subset of this sample, structural imaging measures (P-SZ, n = 133; NP-SZ, n = 67; controls, n = 310) were calculated using Freesurfer 6.0. Group contrasts were run using analysis of covariance, controlling for age, sex, race and site, p-values were corrected using False Discovery Rate (FDR) and were repeated excluding the residual subtype. Compared to NP-SZ (with and without the residual subtype), P-SZ displayed fewer negative symptoms, faster speed of processing, larger bilateral hippocampus, right amygdala and their subfield volumes. Additionally, NP-SZ (with residual subtype) displayed fewer depressive symptoms and higher left transverse temporal cortical thickness (CT) but NP-SZ without residual subtype showed lower GAF scores and worse digit sequencing compared to P-SZ. No differences in positive symptoms and functioning (global or social) were detected. Subtle but significant differences were seen in cognition, symptoms, CT and subcortical volumes between P-SZ and NP-SZ. While the magnitude of these differences is not large enough to justify them as distinct categories, the paranoid- nonparanoid distinction in schizophrenia merits further investigation.

Identifiants

pubmed: 32507376
pii: S0920-9964(20)30087-6
doi: 10.1016/j.schres.2020.02.011
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-104

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have declared that there are no conflicts of interest in relation to the subject of this study.

Auteurs

Olivia Lutz (O)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

Paulo Lizano (P)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA, United States of America.

Suraj Sarvode Mothi (SS)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

Victor Zeng (V)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

Rachal R Hegde (RR)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

Dung T Hoang (DT)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

Philip Henson (P)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.

Roscoe Brady (R)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA, United States of America.

Carol A Tamminga (CA)

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, United States of America.

Godfrey Pearlson (G)

Department of Psychiatry, Yale University, New Haven, CT, United States of America.

Brett A Clementz (BA)

Department of Psychology and Neuroscience, Bio-Imaging Research Center, University of Georgia, Athens, GA, United States of America.

John A Sweeney (JA)

Department of Psychiatry, University of Cincinnati, Cincinnati, OH, United States of America.

Matcheri S Keshavan (MS)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA, United States of America. Electronic address: mkeshava@bidmc.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH